International Association for the Study of Lung Cancer Names Research Award after Dr. Fred R. Hirsch
March 2nd 2020The International Association for the Study of Lung Cancer (IASLC) announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC CEO, Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology and Associate Director of Biomarker Discovery at The Tisch Cancer Institute at Mount Sinai and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.
Read More
ACCC Quality Improvement Workshops Address the Need for Improved Chronic Lymphocytic Leukemia Care
February 5th 2020The Association of Community Cancer Centers is pleased to announce that its Multidisciplinary Chronic Lymphocytic Leukemia Care education project is conducting a series of quality improvement workshops to promote the optimal care and management of patients diagnosed with chronic lymphocytic leukemia.
Read More
New Chapter Opens in Bladder Cancer Treatment
February 5th 2020For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.
Read More
John Theurer Cancer Center Investigators Report Poor Colorectal Cancer Biomarker Testing Rates
January 14th 2020Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are the first to report poor adherence to genomic profiling guidelines for four biomarkers of metastatic colorectal cancer used to predict response to therapy, choose the most effective treatment, and improve outcomes — showing that only 40% of patients had their tumors tested.
Read More
Brentuximab Vedotin Demonstrates Durable Long-Term PFS Benefit in Hodgkin Lymphoma
December 18th 2019The addition of brentuximab vedotin to standard 3-drug chemotherapy for patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma continued to outperform a 4-drug chemotherapy standard.
Read More
Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer
December 14th 2019Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.
Read More
Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
December 13th 2019A subcutaneous fixed-dose combination of pertuzumab and trastuzumab demonstrated noninferiority to intravenous formulations of the 2 drugs with respect to pharmacokinetics, clinical activity, and safety, a randomized trial demonstrated.
Read More
Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate
December 12th 2019The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.
Read More
Large PFS Gain With Daratumumab in Transplant-Ineligible Myeloma
December 11th 2019More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.
Read More